[144] Legend Biotech Corporation American SEC Filing

Rhea-AI Filing Summary

Legend Biotech Corporation (LEGN) – Form 144 filing

The filing, marked as LIVE, notifies the SEC of a proposed Rule 144 sale of 307 American Depositary Shares (ADS), valued at approximately $10,551.59. Fidelity Brokerage Services LLC is listed as broker, and the sale is expected to occur on or about 24 June 2025 on NASDAQ.

The ADS were acquired on 20 June 2025 through the vesting of restricted stock awarded as compensation. Outstanding ADS total 367,298,315; therefore, the planned disposition represents less than 0.0001 % of shares outstanding, indicating an immaterial effect on float or control.

The filer, identified in prior activity as Corazon Sanders, previously sold an identical lot of 307 ADS on 25 March 2025 for gross proceeds of $11,153.31. No relationship to the issuer, 10b5-1 plan details, or additional insider roles are disclosed. The signer attests to possessing no undisclosed material adverse information.

Positive

• Sale equals just 0.0001 % of outstanding ADS, suggesting negligible dilution or market impact.

Negative

• Second insider disposition of 307 ADS within three months could signal ongoing selling pressure, albeit at immaterial volume.

Insights

Securities Analyst

TL;DR: 307-share sale is immaterial versus 367 M float; neutral signal though continued insider selling warrants monitoring.

Legend Biotech’s Form 144 covers a tiny fraction of outstanding stock (≈0.0001 %), translating to only about $10.6 k in market value. Such de-minimis size is unlikely to exert price pressure or alter ownership structure. The shares stem from recent restricted-stock vesting, a routine liquidity event. While a prior 307-share sale occurred three months earlier, the pattern is still too small for a definitive insider-sentiment read. No adverse information or special trading plan is cited, keeping the disclosure strictly procedural.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	307	10551.59	367298315	06/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	06/20/2025	Restricted Stock Vesting	Issuer			307	06/20/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Corazon Sanders 2101 Cottontail Lane Somerset NJ 08873	American Depositary Shares	03/25/2025	307	11153.31

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Legend Biotech (LEGN) shares are being sold under this Form 144?

The filer plans to sell 307 American Depositary Shares.

What is the estimated market value of the planned LEGN share sale?

The aggregate market value is $10,551.59.

When is the approximate sale date for the 307 LEGN ADS?

The filing lists an approximate sale date of 24 June 2025.

How many Legend Biotech ADS are currently outstanding?

The company reports 367,298,315 ADS outstanding.

Has the filer sold Legend Biotech shares in the last three months?

Yes, 307 ADS were sold on 25 March 2025 for gross proceeds of $11,153.31.